三阴性乳腺癌免疫检查点免疫治疗的进展

Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.

CCL19 武装的溶瘤腺病毒与表达 CCR7 的 CAR-T 细胞协同抑制卵巢肿瘤生长

CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth.

横纹肌肉瘤中的 CAR-T 细胞免疫治疗

CAR-T cell immunotherapy in rhabdomyosarcoma.

通过整合这些进展，合理设计的多模式治疗有望克服耐药机制并改善难治性横纹肌肉瘤的结局，为这种历史上难以治愈的恶性肿瘤带来希望。

溶瘤病毒 OVV-03 通过免疫调节与特异性 HER2 上调增强针对胶质母细胞瘤的 CAR-T 细胞治疗

Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation.

晚期 HER2 阴性乳腺癌患者瘤内注射 talimogene laherparepvec（T-VEC）联合化疗或内分泌治疗的 Ib 期研究

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-n

肉瘤中的过继性 T 细胞疗法

Adoptive T-Cell Therapy in Sarcomas.

胃癌的先进疗法

Advanced therapies for stomach cancer.

溶瘤腺病毒免疫治疗增强同种异体过继 HER2.CAR-NK 抗胰腺导管腺癌功能

Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma.

乳腺癌免疫治疗：超越免疫检查点抑制剂

Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.

胃癌的靶向治疗与免疫治疗：合理策略、新进展、挑战与未来展望

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives.